Cargando…
How we make cell therapy in Italy
In the 21st century scenario, new therapeutic tools are needed to take up the social and medical challenge posed by the more and more frequent degenerative disorders and by the aging of population. The recent category of advanced therapy medicinal products has been created to comprise cellular, gene...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548721/ https://www.ncbi.nlm.nih.gov/pubmed/26316716 http://dx.doi.org/10.2147/DDDT.S80403 |
_version_ | 1782387221554266112 |
---|---|
author | Montemurro, Tiziana Viganò, Mariele Budelli, Silvia Montelatici, Elisa Lavazza, Cristiana Marino, Luigi Parazzi, Valentina Lazzari, Lorenza Giordano, Rosaria |
author_facet | Montemurro, Tiziana Viganò, Mariele Budelli, Silvia Montelatici, Elisa Lavazza, Cristiana Marino, Luigi Parazzi, Valentina Lazzari, Lorenza Giordano, Rosaria |
author_sort | Montemurro, Tiziana |
collection | PubMed |
description | In the 21st century scenario, new therapeutic tools are needed to take up the social and medical challenge posed by the more and more frequent degenerative disorders and by the aging of population. The recent category of advanced therapy medicinal products has been created to comprise cellular, gene therapy, and tissue engineered products, as a new class of drugs. Their manufacture requires the same pharmaceutical framework as for conventional drugs and this means that industrial, large-scale manufacturing process has to be adapted to the peculiar characteristics of cell-containing products. Our hospital took up the challenge of this new path in the early 2000s; and herein we describe the approach we followed to set up a pharmaceutical-grade facility in a public hospital context, with the aim to share the solutions we found to make cell therapy compliant with the requirements for the production and the quality control of a high-standard medicinal product. |
format | Online Article Text |
id | pubmed-4548721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-45487212015-08-27 How we make cell therapy in Italy Montemurro, Tiziana Viganò, Mariele Budelli, Silvia Montelatici, Elisa Lavazza, Cristiana Marino, Luigi Parazzi, Valentina Lazzari, Lorenza Giordano, Rosaria Drug Des Devel Ther Methodology In the 21st century scenario, new therapeutic tools are needed to take up the social and medical challenge posed by the more and more frequent degenerative disorders and by the aging of population. The recent category of advanced therapy medicinal products has been created to comprise cellular, gene therapy, and tissue engineered products, as a new class of drugs. Their manufacture requires the same pharmaceutical framework as for conventional drugs and this means that industrial, large-scale manufacturing process has to be adapted to the peculiar characteristics of cell-containing products. Our hospital took up the challenge of this new path in the early 2000s; and herein we describe the approach we followed to set up a pharmaceutical-grade facility in a public hospital context, with the aim to share the solutions we found to make cell therapy compliant with the requirements for the production and the quality control of a high-standard medicinal product. Dove Medical Press 2015-08-20 /pmc/articles/PMC4548721/ /pubmed/26316716 http://dx.doi.org/10.2147/DDDT.S80403 Text en © 2015 Montemurro et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Methodology Montemurro, Tiziana Viganò, Mariele Budelli, Silvia Montelatici, Elisa Lavazza, Cristiana Marino, Luigi Parazzi, Valentina Lazzari, Lorenza Giordano, Rosaria How we make cell therapy in Italy |
title | How we make cell therapy in Italy |
title_full | How we make cell therapy in Italy |
title_fullStr | How we make cell therapy in Italy |
title_full_unstemmed | How we make cell therapy in Italy |
title_short | How we make cell therapy in Italy |
title_sort | how we make cell therapy in italy |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4548721/ https://www.ncbi.nlm.nih.gov/pubmed/26316716 http://dx.doi.org/10.2147/DDDT.S80403 |
work_keys_str_mv | AT montemurrotiziana howwemakecelltherapyinitaly AT viganomariele howwemakecelltherapyinitaly AT budellisilvia howwemakecelltherapyinitaly AT montelaticielisa howwemakecelltherapyinitaly AT lavazzacristiana howwemakecelltherapyinitaly AT marinoluigi howwemakecelltherapyinitaly AT parazzivalentina howwemakecelltherapyinitaly AT lazzarilorenza howwemakecelltherapyinitaly AT giordanorosaria howwemakecelltherapyinitaly |